SCHEMBL5067351

SCHEMBL5067351

FC(F)(F)O[C]1CCCCC1

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 4/20 0.32
SLC6A3 Q01959 4/20 0.32
SLC6A2 P23975 1/20 0.32
EPHX2 P34913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21224620 0.97 ALDH1A1 (0.31)
SCHEMBL20772172 0.91
SCHEMBL6284651 0.73 DHODH (0.41)
SCHEMBL7009105 0.71
SCHEMBL7848247 0.70 SLC6A3 (0.39) SLC6A4SLC6A3SLC6A2
SCHEMBL21700372 0.68 NISCH (0.45) SLC6A4SLC6A3SLC6A2EPHX2
SCHEMBL1765599 0.63 ALDH1A1 (0.35)
SCHEMBL13737387 0.59 ALDH1A1 (0.33)
SCHEMBL566960 0.58
SCHEMBL11579050 0.58 TSHR (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111630031-B Process for producing quinolin-4 (1H) -one derivative 日本化药株式会社 2024-03-12 CN disclosed
CN-115052856-A 3-alkoxybenzamide derivative and pest control agent 组合化学工业株式会社 2022-09-13 CN disclosed
CN-114650991-A Bridged ring-fused aldehyde pyridine derivative and application thereof 北京伯汇生物技术有限公司 2022-06-21 CN disclosed
US-11267787-B2 Method for producing quinolin-4(1H)-one derivative NIPPON KAYAKU CO., LTD (JP) 2022-03-08 US disclosed
WO-2021153720-A1 3-ALKOXY BENZOIC ACID AMIDE DERIVATIVE, AND PEST CONTROL AGENT クミアイ化学工業株式会社 2021-08-05 WO disclosed
CN-112759593-A Bridged ring-fused aldehyde pyridine derivative and application thereof 北京伯汇生物技术有限公司 2021-05-07 CN disclosed
US-20210070710-A1 METHOD FOR PRODUCING QUINOLIN-4(1H)-ONE DERIVATIVE NIPPON KAYAKU CO., LTD. (JP) 2021-03-11 US disclosed
US-20200392107-A1 CYCLIC AMINE DERIVATIVE AND MEDICAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 2020-12-17 US disclosed
EP-3747879-A1 CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Toray Industries, Inc. (JP) 2020-12-09 EP disclosed
CN-111630031-A Process for producing quinolin-4 (1H) -one derivative 日本化药株式会社 2020-09-04 CN disclosed
CN-111566098-A Cyclic amine derivatives and pharmaceutical use thereof 东丽株式会社 2020-08-21 CN disclosed
WO-2019151270-A1 CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF 東レ株式会社 2019-08-08 WO disclosed
EP-1607463-B1 LIQUID CRYSTAL COMPOSITION DAINIPPON INK & CHEMICALS (JP) 2008-09-24 EP disclosed
US-7405026-B2 Liquid crystal composition DAINIPPON INK AND CHEMICALS, INC. (JP) 2008-07-29 US disclosed
US-20060172089-A1 Liquid crystal composition DAINIPPON INK AND CHEMICALS, INC., (JP) 2006-08-03 US disclosed
EP-1607463-A1 LIQUID CRYSTAL COMPOSITION DAINIPPON INK AND CHEMICALS, INC. (JP) 2005-12-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11267787-B2 Method for producing quinolin-4(1H)-one derivative NQO2, AKR7A2, KEAP1 SLC6A4 2977/4885SLC6A3 4172/4885SLC6A2 3382/4885
US-20200392107-A1 CYCLIC AMINE DERIVATIVE AND MEDICAL USE THEREOF NPR3, SLC10A1, CNR2 SLC6A4 251/4885SLC6A3 88/4885SLC6A2 53/4885
US-20210070710-A1 METHOD FOR PRODUCING QUINOLIN-4(1H)-ONE DERIVATIVE NQO2, AKR7A2, KEAP1 SLC6A4 2977/4885SLC6A3 4172/4885SLC6A2 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.